Biotech · Private company · Corte Madera, CA, US
Ophirex, Inc.
Track this companyFree. Adds Ophirex, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials30 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- VarespladibPhase 2 · Coronavirus Disease 2019ClinicalTrials.gov · fetched Nov 12, 2026
- Varespladib intravenous formPhase 2 · SnakebiteClinicalTrials.gov · fetched Nov 12, 2026
- Varespladib MethylPhase 2 · SnakebitesClinicalTrials.gov · fetched Nov 12, 2026
- varespladib-methyl- oral formPhase 2 · SnakebiteClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)PHASE2 · COMPLETED · started May 30, 2023ClinicalTrials.gov NCT05717062 · fetched Nov 12, 2026
- Broad-spectrum Rapid Antidote: Varespladib Oral for SnakebitePHASE2 · COMPLETED · started Aug 15, 2021ClinicalTrials.gov NCT04996264 · fetched Nov 12, 2026
- Study of Varespladib in Patients Hospitalized With Severe COVID-19PHASE2 · TERMINATED · started Jun 30, 2021ClinicalTrials.gov NCT04969991 · fetched Nov 12, 2026
NIH awards2
- Development of Intravenous Varespladib, a Phospholipase A2 Inhibitor, for the Treatment of Snakebite EnvenomingFiscal year 2025 · $1.1MNIH RePORTER 5R01FD007839-03 · fetched Nov 12, 2026
- Development of Intravenous Varespladib, a Phospholipase A2 Inhibitor, for the Treatment of Snakebite EnvenomingFiscal year 2024 · $886.3KNIH RePORTER 5R01FD007839-02 · fetched Nov 12, 2026